SkylineDx, a Netherlands-based diagnostics company specialising in the research and development of molecular diagnostics for oncology, inflammatory and infectious diseases, announced on Saturday that it will present new data on the prognostic value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma at the American Society of Hematology (ASH) conference.

The results were obtained from the PROMMIS real-world study, conducted in nine academic cancer centers across the United States. The presentation, led by Dr. Noa Biran, Associate Professor at Hackensack Meridian School of Medicine, highlights the significant impact of SKY92 on risk stratification in multiple myeloma patients.

A total of 251 newly diagnosed multiple myeloma patients were followed up for four years to monitor their progression. Results showed that individual chromosomal abnormalities and their co-occurrence had limited prognostic value, with the sole exception of the 1q21 abnormality, which prognostic significance for PFS was exclusive to patients aged 65 years and older. SKY92 proved to be a much stronger predictor of poor outcomes. Patients with the high-risk biomarker SKY92 had significantly worse progression-free survival rates, regardless of whether they had other genetic abnormalities.

SkylineDx said that the research also showed that combining SKY92 results with specific genetic markers like gain(1q21) could offer even more detailed insights. For example, patients flagged as high-risk by both tests had some of the poorest outcomes, underlining the complementary value of using SKY92.

According to the company, this study marks a significant step forward in understanding and treating multiple myeloma. The SKY92 test not only provides a more accurate way to identify high-risk disease but also helps refine how we use existing genetic information. By integrating this advanced technology into routine care, clinicians can better support patients facing this challenging disease.